AEZS-132, a new orally bioavailable PI3K/Erk inhibitor with antitumor effects

被引：0
|
作者：
Seipelt, I. [1 ]
Gerlach, M. [2 ]
Baasner, S. [1 ]
Blumenstein, L. [1 ]
Mueller, G. [2 ]
Aicher, B. [1 ]
Engel, J. [3 ]
Guenther, E. [4 ]
Teifel, M. [1 ]
机构：
[1] Aeterna Zentaris GmbH, Preclin Dev, Frankfurt, Germany
[2] Aeterna Zentaris GmbH, Med Chem, Frankfurt, Germany
[3] Aeterna Zentaris GmbH, Management Board, Frankfurt, Germany
[4] Aeterna Zentaris GmbH, Alliance Management, Frankfurt, Germany
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)71902-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：66 / 66
页数：1
相关论文
共 50 条
  • [21] Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
    Jiang, Hongmei
    Xu, Mai
    Li, Lin
    Grierson, Patrick
    Dodhiawala, Paarth
    Highkin, Maureen
    Zhang, Daoxiang
    Li, Qiong
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (10) : 2144 - 2155
  • [22] Amino-alkyl substituted fused imidazoles: potent, selective and orally bioavailable inhibitors of PI3K
    Pastor, J.
    Martinez, S.
    Alvarez, R. M.
    Varela, C.
    Hernandez, A. I.
    Rodriguez, S.
    Oyarzabal, J.
    Albarran, M.
    Link, W.
    Bischoff, J. R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 62 - 62
  • [23] Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target
    Henley, Zoe A.
    Amour, Augustin
    Barton, Nick
    Bantscheff, Marcus
    Bergamini, Giovanna
    Bertrand, Sophie M.
    Convery, Maire
    Down, Kenneth
    Duempelfeld, Birgit
    Edwards, Chris D.
    Grandi, Paola
    Gore, Paul M.
    Keeling, Steve
    Livia, Stefano
    Mallett, David
    Maxwell, Aoife
    Price, Mark
    Rau, Christina
    Reinhard, Friedrich B. M.
    Rowedder, James
    Rowland, Paul
    Taylor, Jonathan A.
    Thomas, Daniel A.
    Hessel, Edith M.
    Hamblin, J. Nicole
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (02) : 638 - 655
  • [24] Amino-carbonyl substituted fused imidazoles: potent, selective and orally bioavailable inhibitors of PI3K
    Pastor, J.
    Martinez, S.
    Alvarez, R. M.
    Hernandez, A. I.
    Varela, C.
    Garcia, A. B.
    Rabal, O.
    Gonzalez-Granda, M. T.
    Fominaya, J.
    Bischoff, J. R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 61 - 61
  • [25] Duvelisib, a New PI3K Inhibitor for Lymphoid Malignancies
    Lamanna, Nicole
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (10) : 606 - 608
  • [26] Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models
    Bao, Rudi
    Wang, Dagong
    Qu, Hui
    Yin, Ling
    Xu, Guang-Xin
    DellaRocca, Steven
    Borek, Mylissa
    Atoyan, Ruzanna
    Forrester, Jeffrey
    Samson, Maria
    Wang, Jing
    Zhai, Hai-Xaio
    Chan, Mendy
    Lai, Cheng-Jung
    Cai, Xiong
    Qian, Changgeng
    CANCER RESEARCH, 2011, 71
  • [27] Sequential Application of a Cytotoxic Nanoparticle and a PI3K Inhibitor Enhances Antitumor Efficacy
    Pandey, Ambarish
    Kulkarni, Ashish
    Roy, Bhaskar
    Goldman, Aaron
    Sarangi, Sasmit
    Sengupta, Poulomi
    Phipps, Colin
    Kopparam, Jawahar
    Oh, Michael
    Basu, Sudipta
    Kohandel, Mohammad
    Sengupta, Shiladitya
    CANCER RESEARCH, 2014, 74 (03) : 675 - 685
  • [28] Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases
    Erra, Montse
    Taltavull, Joan
    Greco, Angelique
    Javier Bernal, Francisco
    Francisco Caturla, Juan
    Gracia, Jordi
    Dominguez, Maria
    Sabate, Mar
    Paris, Stephane
    Soria, Salome
    Hernandez, Begona
    Armengol, Clara
    Cabedo, Judit
    Bravo, Monica
    Calama, Elena
    Miralpeix, Montserrat
    Lehner, Martin D.
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (01): : 118 - 123
  • [29] Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2014, 24 (05) : 603 - 607
  • [30] Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease
    Amour, Augustin
    Barton, Nick
    Cooper, Anthony W. J.
    Inglis, Graham
    Jamieson, Craig
    Luscombe, Christopher N.
    Morrell, Josie
    Peace, Simon
    Perez, David
    Rowland, Paul
    Tame, Chris
    Uddin, Sorif
    Vitulli, Giovanni
    Wellaway, Natalie
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (15) : 7239 - 7251
12345